
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2006-06-30 | 2007-06-30 | 2008-06-30 | 2007-06-30 | 2008-06-30 | |
Income Statement | ||||||
Revenue | $13.1M | $13.5M | $11.9M | $2.8M | $2.7M | |
Gross Profit | -- | -- | -- | -- | -- | |
Operating Income | -- | -- | -- | -$34M | -$34.2M | |
EBITDA | -- | -- | -- | -$34M | -$34.2M | |
Diluted EPS | -- | -- | -- | -$40.30 | -$43.33 |
Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $7.3M | -- | -- | $7.1M | $4.1M | |
Total Assets | $15.8M | -- | -- | $18.6M | $14.4M | |
Current Liabilities | $3.5M | -- | -- | $5M | $17.2M | |
Total Liabilities | $6.1M | -- | -- | $10.6M | $21.1M | |
Total Equity | $9.7M | -- | -- | $8M | -$6.7M | |
Total Debt | -- | -- | -- | $1.2M | $423.8K |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 | 2021-12-31 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$3.5M | -- | -- | -$9M | -$8.3M | |
Cash From Investing | $1.7M | -- | -- | -- | $9.4K | |
Cash From Financing | $2.6M | -- | -- | $17.3M | $12.2K | |
Free Cash Flow | -$3.5M | -- | -- | -- | -- |
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
In the current month, KZIA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KZIA average analyst price target in the past 3 months is $2.98.
According to analysts, the consensus estimate is that Kazia Therapeutics share price will rise to $2.98 per share over the next 12 months.
Analysts are divided on their view about Kazia Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kazia Therapeutics is a Sell and believe this share price will drop from its current level to $2.98.
The price target for Kazia Therapeutics over the next 1-year time period is forecast to be $2.98 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Kazia Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
You can purchase shares of Kazia Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kazia Therapeutics shares.
Kazia Therapeutics was last trading at $0.95 per share. This represents the most recent stock quote for Kazia Therapeutics. Yesterday, Kazia Therapeutics closed at $0.90 per share.
In order to purchase Kazia Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
For the last few years, earnings growth from the tech…
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Market Cap: $3.3T
P/E Ratio: 36x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.7T
P/E Ratio: 37x
Guardant Health [GH] is up 1.1% over the past day.
Teradyne [TER] is down 0.36% over the past day.
Limbach Holdings [LMB] is down 4.39% over the past day.